Neoadjuvant chemotherapy (NACT) has become the standard of care for high‐risk breast
cancer, including triple‐negative (TNBC) and HER2‐positive disease. As a result, handling …

Immune checkpoint inhibitors (ICIs) have changed therapy strategies in breast cancer (BC)
patients suffering from triple-negative breast cancer (TNBC). For example, in Europe the anti …

Despite advances in clinical management, a proportion of patients with early-stage triple-
negative breast cancer (TNBC) recur after local treatment. The concept of neoadjuvant …

Immunotherapy is revolutionary and changing the cancer therapy of multiple solid tumors.
Immunotherapy began with discovering the proteins of immune checkpoints such as …

Neoadjuvant chemotherapy (NACT) is used increasingly in the treatment of invasive breast
cancer and presents challenges for the pathologist in the handling and interpretation of …

Invasive breast cancer is generally treated with some form of systemic “adjuvant” therapy,
including combinations of cytotoxic chemotherapy, HER2 targeted therapy, immunotherapy …

Neoadjuvant systemic therapy is becoming more commonly used in patients with earlier
stages of breast cancer. To assess tumour response to neoadjuvant chemotherapy …

Triple-negative breast cancers (TNBC) are an immunohistochemically defined subset of
breast cancer that is negative for the estrogen receptor (ER), progesterone receptor (PR) …

Simple Summary Immune checkpoint inhibitors (ICI) are now part of the therapeutical
arsenal for cancers at several sites and in several settings. PD-L1 expression is assessed to …

Breast cancer, one of the most common cancers in women, has various treatment
modalities. Neoadjuvant therapy (NAT) has been used in many clinical trials because it is …